The problem of anti-pig antibodies in pig-to-primate xenografting: current and novel methods of depletion and/or suppression of production of anti-pig antibodies

被引：70

作者：

Alwayn, IPJ ^{[1
]}

Basker, M ^{[1
]}

Buhler, L ^{[1
]}

Cooper, DKC ^{[1
]}

机构：

[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr,MGH E, Boston, MA 02129 USA

来源：

XENOTRANSPLANTATION | 1999年 / 6卷 / 03期

关键词：

anti-alpha-Gal antibodies; anti-CD40 ligand monoclonal antibody; B-cells; pig-to-primate; tolerance; xenotransplantation;

D O I：

10.1034/j.1399-3089.1999.00030.x

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The role of antibodies directed against Gal alpha l-3Gal (alpha-Gal) epitopes in porcine-to-primate xenotransplantation has been widely studied during the past few years. These antibodies (anti-alpha-Gal) have been associated with both hyperacute rejection and acute vascular rejection of vascularized organs. Depletion and (temporary or permanent) suppression of production of anti-alpha-Gal seem to be essential to the long-term survival of these organs, even when the ultimate aim is accommodation or tolerance. Although more than 95% depletion of anti-alpha-Gal can be achieved by the use of immunoaffinity column technology, to date no regimen has been successful in preventing the return of anti-alpha-Gal (from continuing production). In this review, we discuss current and novel methods for achieving depletion or inhibition (i.e. extracorporeal immunoadsorption, anti-idiotypic antibodies, the intravenous infusion of immunoglobulin or oligosaccharides) and suppression of production (i.e. irradiation, pharmacologic agents, specific monoclonal antibodies, immunotoxins) of anti-alpha-Gal antibodies.

引用

页码：157 / 168

页数：12

共 92 条

[1]

ALEXANDRE GPJ, 1987, TRANSPLANT P, V19, P4538

[2]

ALEXANDRE GPJ, 1989, XENOGRAFT, P25

[3] MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF A MURINE LIGAND FOR CD40 [J].

ARMITAGE, RJ ;

FANSLOW, WC ;

STROCKBINE, L ;

SATO, TA ;

CLIFFORD, KN ;

MACDUFF, BM ;

ANDERSON, DM ;

GIMPEL, SD ;

DAVISSMITH, T ;

MALISZEWSKI, CR ;

CLARK, EA ;

SMITH, CA ;

GRABSTEIN, KH ;

COSMAN, D ;

SPRIGGS, MK .

NATURE, 1992, 357 (6373) :80-82

[4] Removal of primate xenoreactive natural antibodies by extracorporeal perfusion of pig kidneys and livers [J].

Azimzadeh, A ;

Meyer, C ;

Watier, H ;

Beller, JP ;

Chenard-Neu, MP ;

Kieny, R ;

Boudjema, K ;

Jaeck, D ;

Cinqualbre, J ;

Wolf, P .

TRANSPLANT IMMUNOLOGY, 1998, 6 (01) :13-22

[5] Accommodation of vascularized xenografts: Expression of ''protective genes'' by donor endothelial cells in a host Th2 cytokine environment [J].

Bach, FH ;

Ferran, C ;

Hechenleitner, P ;

Mark, W ;

Koyamada, N ;

Miyatake, T ;

Winkler, H ;

Badrichani, A ;

Candinas, D ;

Hancock, WW .

NATURE MEDICINE, 1997, 3 (02) :196-204

[6] BARRIERS TO XENOTRANSPLANTATION [J].

BACH, FH ;

ROBSON, SC ;

WINKLER, H ;

FERRAN, C ;

STUHLMEIER, KM ;

WRIGHTON, CJ ;

HANCOCK, WW .

NATURE MEDICINE, 1995, 1 (09) :869-873

[7]

Bach FH, 1991, XENOTRANSPLANTATION

[8] Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124):: in vitro and in vivo studies [J].

Bolognesi, A ;

Tazzari, PL ;

Olivieri, F ;

Polito, L ;

Lemoli, R ;

Terenzi, A ;

Pasqualucci, L ;

Falini, B ;

Stirpe, F .

BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (01) :179-188

[9] Simultaneous expression by porcine aorta endothelial cells of glycosphingolipids bearing the major epitope for human xenoreactive antibodies (Gal alpha 1-3Gal), blood group H determinant and N-glycolylneuraminic acid [J].

Bouhours, D ;

Pourcel, C ;

Bouhours, JF .

GLYCOCONJUGATE JOURNAL, 1996, 13 (06) :947-953

[10]

BUHLER L, COMMUNICATION

← 1 2 3 4 5 6 7 8 9 10 →